6892 Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices 

Licensing Contact: To license this 

technology, please contact Carol A. 

Salata at 240–627–3727; csalata@

niaid.nih.gov. 

Dated: January 8, 2021. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–01490 Filed 1–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Cell Therapies 

for Cancer 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Ziopharm 

Oncology, Inc. (‘‘Ziopharm’’), 

headquartered in Boston, MA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before February 9, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Andrew Burke, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 

Telephone: (240) 276–5484; Email: 

andy.burke@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

Group B 

E–173–2020: T Cell Receptors 

Recognizing R273C or Y220C 

Mutation in P53 

1. U.S. Provisional Patent Application 

63/074,747, filed September 4, 2020 

(E–173–2020–0–US–01). 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

fields of use may be limited to the 

following: 

Fields of Use Applying to Intellectual 

Property Group B 

‘‘Development, manufacture and 

commercialization of autologous, 

peripheral blood T cell therapy products 

engineered by transposon-mediated 

gene transfer to express T cell receptors 

reactive to mutated P53, as claimed in 

the Licensed Patent Rights, for the 

treatment of human cancers. 

Specifically excluded from this field of 

use are CRISPR-engineered peripheral 

blood T cell therapy products for the 

treatment of human cancers. 

Development, manufacture and 

commercialization of companion 

diagnostics approved or cleared by the 

FDA or equivalent foreign regulatory 

agency for Licensee-proprietary T cell 

therapy products.’’ 

Intellectual Property Group B is 

primarily directed to isolated TCRs 

reactive to mutated tumor protein 53 

(TP53 or P53), within the context of 

several HLAs. P53 is the archetypal 

tumor suppressor gene and the most 

frequently mutated gene in cancer. 

Contemporary estimates suggest that 

>50% of all tumors carry mutations in 

P53. Because of its prevalence in cancer 

and its restricted expression to 

precancerous and cancerous cells, this 

antigen may be targeted on mutant P53- 

expressing tumors with minimal normal 

tissue toxicity. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 14, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–01487 Filed 1–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Certain Fusion 

Proteins and Their Use for the 

Treatment of Humans With Short 

Stature 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development and the National 

Cancer Institute, both institutes of the 

National Institutes of Health, 

Department of Health and Human 

Services, are contemplating the grant of 

an Exclusive Patent License to practice 

the inventions embodied in the Patents 

and Patent Applications listed in the 

Supplementary Information section of 

this Notice to EpifiZa Inc. of Montreal, 

QC (Canada). 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before February 9, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Richard T. Girards, Jr., Esq., 

MBA, Senior Technology Transfer 

Manager, National Institutes of Health, 

NCI Technology Transfer Center by 

email (richard.girards@nih.gov) or 

phone (240–276–6825). 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–003–2014: Agents That Specifically 

Bind Matrilin–3 and Their Use/Cartilage 

Targeting Agents and Their Use 

1. United States Provisional Patent 

Application No. 61/927,904, filed 15 

January 2014 (HHS Reference No. E– 

003–2014–0–US–01); 

2. United States Patent No. 

10,323,083, issued 18 June 2019 (HHS 

Reference No. E–003–2014–0–US–06); 

3. United States Patent Application 

No. 16/391,101, filed 22 April 2019 


jbell on DSKJLSW7X2PROD with NOTICES